Japan's core machinery orders in June increased by 9.7% compared to the previous month. This marks a rebound from a 12.4% decline in May, indicating an improvement in leading indicators that reflect corporate capital investment trends. The Cabinet Office's Economic and Social Research Institute announced that private core machinery orders rose by 9.7% on a seasonally adjusted basis in June. The market expectation was a 7.8% increase. Overall machinery orders increased by 0.4% from the previous month, and while the monthly core orders rebounded significantly, the overall increase in orders was relatively modest. On a quarterly basis, total machinery orders from April to June increased by 11.3% compared to the previous quarter, but private core machinery orders only saw a 0.2% increase. Core machinery orders exclude volatile categories such as ships and power companies, reflecting orders for corporate equipment and facilities. The Cabinet Office expects total machinery orders from July to September to decrease by 0.1% compared to the previous quarter, while private core machinery orders are projected to increase by 4.9%. This forecast is based on aggregated data from 280 machinery manufacturers, and actual capital investment trends may vary depending on manufacturing orders, exchange rates, and changes in external demand.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.


Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.















Long-end U.S. Treasury yields surged to multi-year highs, pressuring technology, semiconductor, storage, and optical communication stocks and driving a clear cooling in market risk appetite. At the same time, Anthropic’s revenue came in below some bullish expectations, prompting investors to reassess the AI growth narrative; Unitree Robotics officially listed on the STAR Market, extending momentum in robotics and embodied AI; while SpaceX and other commercial space names showed relative resilience. Investors are now focused on tonight’s Federal Reserve minutes for clearer signals on the policy path and broader market sentiment.













Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.